Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on immune modulation through selective ITK (interleukin-2-inducible T-cell kinase) inhibition. Its lead candidate, soquelitinib, is an oral small molecule in late-stage trials for peripheral T-cell lymphoma and earlier studies in autoimmune and inflammatory conditions such as atopic dermatitis. The pipeline also includes other immuno-oncology agents aimed at reshaping T-cell and NK-cell responses in cancer and immune disease.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -8 | — |
| Q3 2025 | 0 | — | -10.2 | — |
| Q4 2025 | 0 | — | -12.3 | — |
| Q1 2026 | 0 | — | -13.7 | — |
| Q2 2026 | 0 | — | -18 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: World Acceptance Corporation (WRLD), Ardelyx, Inc. (ARDX), Service Properties Trust (SVC), Alumis Inc. (ALMS), Kelly Services, Inc. (KELYB), Independent Bank Corporation (IBCP)